Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C21H16FN7O |
| Molecular Weight | 401.3964 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H](NC1=C2NC=NC2=NC=N1)C3=NC4=C(C=C(F)C=C4)C(=O)N3C5=CC=CC=C5
InChI
InChIKey=DOCINCLJNAXZQF-LBPRGKRZSA-N
InChI=1S/C21H16FN7O/c1-12(27-19-17-18(24-10-23-17)25-11-26-19)20-28-16-8-7-13(22)9-15(16)21(30)29(20)14-5-3-2-4-6-14/h2-12H,1H3,(H2,23,24,25,26,27)/t12-/m0/s1
| Molecular Formula | C21H16FN7O |
| Molecular Weight | 401.3964 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
GS-9820 (formerly CAL-120) is an oral, small molecule delta selective Phosphatidylinositol 3-kinases (PI3 kinase) inhibitor, a first in class compound, with greater than 200-fold selectivity in cell-based assays for the delta isoform as compared to other class isoforms. GS-9820 is designed to induce cancer cell death and inhibit signaling pathways associated with cancer cell dependence on the tumor microenvironment. GS-9820 is on the phase I of clinical trial, where has to be determined the appropriate dosing regimen of drug in subjects with lymphoid malignancies.
Approval Year
Sample Use Guides
200 mg administered twice a day. Escalation will proceed to the maximum tolerated dose (MTD), defined as the highest tested dose associated with a rate of dose-limiting toxicities (DLT) of < 33% during the first 4 weeks of therapy.
Route of Administration:
Oral
GS-9820 (ACALISIB) was characterized using in vitro activity assays in the presence of 10 uM GS-9820. GS-9820 was more selective for PI3Kδ relative to other PI3K class I enzymes (IC50: PI3Kα, 5,441 nm; PI3Kβ, 3,377 nm; PI3Kγ, 1,389 nm; and PI3Kδ, 12.7 nm). GS-9820 was also 103-fold more selective against PI3Kδ than against related kinases, such as CIIβ, hVPS34, DNAPK, and mammalian target of rapamycin.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 10:31:50 GMT 2023
by
admin
on
Sat Dec 16 10:31:50 GMT 2023
|
| Record UNII |
OVW60IDW1D
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C129825
Created by
admin on Sat Dec 16 10:31:50 GMT 2023 , Edited by admin on Sat Dec 16 10:31:50 GMT 2023
|
||
|
NCI_THESAURUS |
C2152
Created by
admin on Sat Dec 16 10:31:50 GMT 2023 , Edited by admin on Sat Dec 16 10:31:50 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
9812
Created by
admin on Sat Dec 16 10:31:50 GMT 2023 , Edited by admin on Sat Dec 16 10:31:50 GMT 2023
|
PRIMARY | |||
|
11618268
Created by
admin on Sat Dec 16 10:31:50 GMT 2023 , Edited by admin on Sat Dec 16 10:31:50 GMT 2023
|
PRIMARY | |||
|
870281-34-8
Created by
admin on Sat Dec 16 10:31:50 GMT 2023 , Edited by admin on Sat Dec 16 10:31:50 GMT 2023
|
PRIMARY | |||
|
100000175794
Created by
admin on Sat Dec 16 10:31:50 GMT 2023 , Edited by admin on Sat Dec 16 10:31:50 GMT 2023
|
PRIMARY | |||
|
OVW60IDW1D
Created by
admin on Sat Dec 16 10:31:50 GMT 2023 , Edited by admin on Sat Dec 16 10:31:50 GMT 2023
|
PRIMARY | |||
|
DB15407
Created by
admin on Sat Dec 16 10:31:50 GMT 2023 , Edited by admin on Sat Dec 16 10:31:50 GMT 2023
|
PRIMARY | |||
|
C103277
Created by
admin on Sat Dec 16 10:31:50 GMT 2023 , Edited by admin on Sat Dec 16 10:31:50 GMT 2023
|
PRIMARY | |||
|
CHEMBL3545397
Created by
admin on Sat Dec 16 10:31:50 GMT 2023 , Edited by admin on Sat Dec 16 10:31:50 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
